The researchers reported that abatacept was safe, with similar rates of serious adverse events in both the treatment and placebo groups and no safety concerns linked to the drug.
Overall, the findings suggest that early, targeted immune therapy can delay the onset of RA in high risk individuals, supporting further research into preventive strategies for autoimmune diseases.
More detail at;